<DOC>
	<DOCNO>NCT00295308</DOCNO>
	<brief_summary>Background : - Though drug buprenorphine effectively treat dependence opioids like heroin , abstinent patient relapse use treatment . This relapse may trigger stress stressful situation , buprenorphine probably specific protective effect situation . Buprenorphine probably also specific effect relapse cocaine use . - Research show clonidine , drug originally prescribe treat high blood pressure symptom opioid withdrawal , help block stress-induced relapse heroin cocaine seek rat . Researchers interested study whether combination clonidine buprenorphine may effective prevent drug relapse administer one medication alone . Objectives : - To determine whether clonidine , give abstinent patient maintain buprenorphine , effective placebo prevent relapse heroin cocaine use . Eligibility : - Individuals 18 50 year age current cocaine heroin user seek treatment . Design : - The study last 36 week , four phase treatment follow-up evaluation . Three time week , participant ask report illicit drug use provide urine breath sample . Throughout study , participant receive individual counseling weekly 40 60 minute session . Other sample test schedule require study researcher . - Patients stabilized daily buprenorphine first 14 day study . - Weeks 1 8 : Participants receive voucher regular substance-free urine sample . Those successfully complete phase continue next part study . - Weeks 7 9 : Participants receive either clonidine placebo along buprenorphine . The dose clonidine stabilize time . - Weeks 9 22 : Participants continue receive either clonidine placebo along buprenorphine . During part study , participant keep electronic diary record drug use craving record data mood , stress level , activity . - Weeks 23 28 : Participants stop take clonidine placebo , continue buprenorphine treatment . Participants continue keep electronic diary . - Weeks 29 36 : Participants choice transfer community clinic transfer gradually reduce dos buprenorphine end study . - Participants return follow-up visit urine sample 6 month end study .</brief_summary>
	<brief_title>Clonidine Relapse Prevention Buprenorphine-Maintenance Patients</brief_title>
	<detailed_description>Background . Though buprenorphine effectively treat opioid dependence , abstinent patient relapse maladaptive use opioids treatment . Relapse may trigger stress . Rodent study demonstrate stress induce relapse heroin cocaine use ( Erb , et al. , 1996 ; Shaham , et al. , 1996 ; Shaham Stewart , 1995 ) . In rodent model , stress-induced relapse heroin cocaine seek block alpha-2 adrenergic agonist clonidine . In study , clonidine compare placebo prevent relapse opioid abuse opioid maintain patient achieve abstinence buprenorphine contingency management . Scientific goal . To determine whether clonidine , give abstinent patient maintain buprenorphine , prevents relapse opioid use effectively placebo . Participant population . 300 opioid-dependent outpatient ( 120 evaluable ) . Target enrollment include 40 persent woman 60 percent minority ( mostly African-American ) . Experimental design method . The study randomize double-blind clinical trial . Two treatment group study ( 60/group ) , one receiving clonidine receive placebo . Assignment treatment group randomize . All patient receive buprenorphine daily ( 8 mg 24 mg SL ) individual counseling weekly throughout 28 week treatment . In order establish abstinence prior clonidine induction , one week stabilization buprenorphine , receive contingent voucher opioid-negative urine specimen 8 week ( week 1-8 ) . Patients abstinent illicit opioids week 5 6 randomized receive clonidine ( 0.3 mg oral dose ) clonidine placebo week 9 20 . Participants abstinent switch methadone four week ( usual dose 50 mg 100 mg ) follow eight week methadone taper . Assignment clonidine placebo double-blind . Weeks 21 22 include clonidine taper avoid rebound hypertension . From week 23-28 , participant receive buprenorphine counseling , offer assistance transfer another program ; transfer undergo 8-week buprenorphine taper . The primary outcome measure long duration opioid abstinence , time relapse , proportion opioid-negative urine specimen time Intervention phase . In addition , fluctuation drug use , drug craving , stress , HIV-risk behavior injection drug use assess via ecological momentary assessment ( EMA ) . Benefits participant and/or society . Participants receive buprenorphine , drug counseling , contingency-management therapy . The buprenorphine voucher intervention likely reduce participant ' use opioids . Counseling include reduction HIV risk behavior . Risks participant . Participants may experience side effect clonidine , buprenorphine , methadone discomfort withdrawal drug . In particular , discontinuation clonidine may cause rebound hypertension . The EMA component study may generate assessment burden .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age 18 60 2 . Evidence physical dependence opioids ( selfreport , urine screen , physical exam ) 3 . Seeking treatment opioid dependence 4 . Able attend treatment clinic 7 days/week EXCLUSION CRITERIA : General 1 . Poor venous access 2 . Urologic condition would inhibit urine collection 3 . Pregnancy breastfeed 4 . Failure agree use medically effective form contraception study ( woman sexually active male partner able get pregnant ) . Acceptable form contraception study include : hormonal contraceptive ( birth control pill , injectable hormone , vaginal ring hormone ) , surgical sterility ( tubal ligation hysterectomy ) ; IUD ; Diaphragm spermicide ; Condom spermicide 5 . Current physical dependence alcohol sedativehypnotics , e.g . benzodiazepine Psychiatric 1 . Cognitive impairment severe enough preclude informed consent valid response questionnaire ( Shipley Institute Living scale estimate fullscale IQ le 80 ) 2 . History schizophrenia DSMIV psychotic disorder 3 . History bipolar disorder 4 . Current Major Depressive Disorder Medical 1 . Any active untreated medical illness view investigator would compromise participation research 2 . Allergy intolerance either buprenorphine clonidine 3 . Cerebrovascular disease 4 . Conduction disturbance ( e.g. , seconddegree heart block , thirddegree heart block , atrial fibrillation , ventricular tachycardia ) arrhythmias 5 . Myocardial infarction , document coronary artery disease 6 . Congestive heart failure 7 . Chronic renal failure , estimate Cr &gt; 2.0 8 . CD4 &lt; 200 evidence severely compromise immune system /AIDS 9 . Marked , sustain bradycardia ( HR &lt; 45 bpm ) three separate occasion 10 . Marked , sustain low blood pressure ( SBP &lt; 95 DBP &lt; 40 mm Hg ) three separate reading 11 . Marked , sustain high blood pressure ( SBP &gt; 160 mm Hg , DBP &gt; 100 mm Hg ) several reading , without antihypertensive medication . 12 . ECG change suggestive acute ischemia , clinical important arrhythmia , leave bundle branch block , change concern MRP exclude participant . If accompany cardiovascular complaint chest pain syncope , less specific ECG finding also exclude patient . When doubt , ECG send cardiology prn basis manual reading . 13 . Orthostatic hypotension ( upon stand 3 minute , 20 mm Hg decrease systolic blood pressure 10 mmHg decrease diastolic blood pressure accompany increase 20 bpm heart rate ) two separate reading . Taking contraindicated medication 1 . Beta blocker 2 . Tricyclic antidepressant 3 . Antipsychotics 4 . Mah huang 5 . Yohimbe 6 . Ephedra 7 . Sildenafil citrate ( Viagra ) . Sildenafil citrate dos &gt; 25mg take within 4 hour take alpha blocker produce significant symptomatic hypotension ( Pfizer ) . Of note , Viagra , like buprenorphine , metabolize cytochrome P450 3A4 . Ingestion buprenorphine could potentate effect sildenafil citrate could extent period safety &gt; 4 hr alpha blocker could take Viagra ingestion . Family history sudden cardiac death age &lt; 50 Lab Test Lab Values : WBC* &lt; 1,500 &gt; 13,000 # /CUMM HCT &lt; 33 &gt; 49 Percent Platelets &lt; 100 &gt; 500 K/CUMM Sodium &lt; 132 &gt; 149 MEQ/L Potassium &lt; 3.5 &gt; 5.2 MEQ/L Calcium &lt; 8.4 &gt; 10.5 MG/DL Magnesium &lt; 1.3 &gt; 3 MG/DL &lt; TAB &gt; BUN &gt; 35 MG/DL Cr &lt; TAB &gt; &gt; 2.0 MG/DL &lt; TAB &gt; Alk Phos &lt; TAB &gt; &gt; 200 U/L AST &lt; TAB &gt; &gt; 200 U/L ALT &lt; TAB &gt; &gt; 200 U/L GGT &lt; TAB &gt; &gt; 400 U/L Albumin &lt; TAB &gt; &lt; 3 GM/DL Total bilirubin &gt; 2.0 MG/DL Direct bilirubin &gt; 0.4 MG/DL TSH &lt; TAB &gt; &lt; 0.27 &gt; 4.2 UIU/ML &lt; TAB &gt; *Leukocytosis prompt investigation clearance. &lt; TAB &gt;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 17, 2014</verification_date>
	<keyword>Opioid Dependence</keyword>
	<keyword>Clonidine</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Opioid Abstinence</keyword>
	<keyword>Relapse</keyword>
</DOC>